Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream

Background: Efficacy of ruxolitinib cream, a topical Jak1/Jak2 inhibitor, was demonstrated in a phase 2 trial in patients with vitiligo. Objective: This study aimed to characterize circulating inflammatory biomarker profiles in patients who demonstrated ≥50% improvement in facial Vitiligo Area Scori...

Descripción completa

Detalles Bibliográficos
Autores principales: Howell, Michael D., Kuo, Fiona I., Rumberger, Beth, Boarder, Erika, Sun, Kang, Butler, Kathleen, Harris, John E., Grimes, Pearl, Rosmarin, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568564/
https://www.ncbi.nlm.nih.gov/pubmed/37840766
http://dx.doi.org/10.1016/j.xjidi.2023.100230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568564/
https://www.ncbi.nlm.nih.gov/pubmed/37840766
http://dx.doi.org/10.1016/j.xjidi.2023.100230

Ejemplares similares